SCHEMBL4913816

SCHEMBL4913816

CC(C)(C)N(C(=O)O)[C@@H](CC(=O)N1CC[C@@H](NC(=O)C2CC2)C1)Cc1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 11/20 0.42
KDM5B Q9UGL1 1/20 0.40
C3AR1 Q16581 1/20 0.39
EPHX2 P34913 2/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4919769 1.00 KDM5A (0.42) KDM5AKDM5BC3AR1EPHX2KMT2A
SCHEMBL4926818 0.90 PKM (0.44) KDM5AC3AR1KMT2A
SCHEMBL4914073 0.90 PKM (0.44) KDM5AC3AR1KMT2A
SCHEMBL8474193 0.81 DPP4 (0.55)
SCHEMBL8474122 0.81 DPP4 (0.55)
SCHEMBL4923075 0.80 KDM5B (0.43) KDM5AKDM5BC3AR1EPHX2KMT2A
Trifluoroacetic Acid SCHEMBL4916271 0.80 DPP4 (0.50)
Trifluoroacetic Acid SCHEMBL4922189 0.80 DPP4 (0.50)
SCHEMBL8474235 0.79 SCN9A (0.45) KMT2A
SCHEMBL8493039 0.79 SCN9A (0.45) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275086-A1 Dpp-Iv Inhibitors SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2008-11-06 US disclosed
EP-1702916-A1 DPP-IV inhibitors Santhera Pharmaceuticals (Schweiz) GmbH (CH) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275086-A1 Dpp-Iv Inhibitors DPP4, DPP7, DPP3 KDM5A 1036/4885KDM5B 716/4885C3AR1 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.